Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively ddrug-resistant pseudomonas aeruginosa clinical isolates from a spanish Hospital
López-Calleja, Ana Isabel ; Morilla, Elena ; Nuñez, Rossi ; Fernández Esgueva, Marta ; Sahagún, Juan (Universidad de Zaragoza) ; García-Lechuz, Juan Manuel ; Ferrer Cerón, Isabel ; Viñuelas, Jesús (Universidad de Zaragoza) ; Rezusta, Antonio (Universidad de Zaragoza)
Resumen: Objectives. Our objective was to evaluate the in vitro activity of ceftolozane-tazobactam against multidrugresistant (MDR) and extensively drug-resistant (XDR) non metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates at Hospital Universitario Miguel Servet (Zaragoza, Spain) from February 2016 to October 2017. Material and methods. We evaluated the in vitro activity of ceftolozane-tazobactam and other antipseudomonal antibiotics against 12 MDR and 117 XDR non metallo-β-lactamase producing P. aeruginosa isolates. Ceftolozane-tazobactam minimal inhibitory concentrations (MICs) were determined by MIC gradient diffusion test strip. Results. Among the 129 MDR/XDR isolates included, 119 (92.2%) were susceptible to ceftolozane-tazobactam, and ten (7.8%) were resistant. MIC50 was 2 mg/L, and MIC90 4 mg/L. Ceftolozane-tazobactam was the second most active antibiotic after colistin, overtaking amikacin. Conclusions. Ceftolozane-tazobactam is a valuable treatment option for MDR and XDR P. aeruginosa infections in our setting.
Idioma: Inglés
Año: 2019
Publicado en: Revista española de quimioterapia 32, 1 (2019), 68-72
ISSN: 0214-3429
Factor impacto JCR: 1.132 (2019)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 246 / 270 = 0.911 (2019) - Q4 - T3
Categ. JCR: MICROBIOLOGY rank: 121 / 133 = 0.91 (2019) - Q4 - T3
Factor impacto SCIMAGO: 0.287 - Medicine (miscellaneous) (Q3) - Pharmacology (Q3) - Microbiology (medical) (Q3)
Tipo y forma: Article (Published version)
Área (Departamento): Área Microbiología (Dpto. Microb.Med.Pr.,Sal.Públ.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.
Exportado de SIDERAL (2026-01-13-22:07:41)
Visitas y descargas
Idioma: Inglés
Año: 2019
Publicado en: Revista española de quimioterapia 32, 1 (2019), 68-72
ISSN: 0214-3429
Factor impacto JCR: 1.132 (2019)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 246 / 270 = 0.911 (2019) - Q4 - T3
Categ. JCR: MICROBIOLOGY rank: 121 / 133 = 0.91 (2019) - Q4 - T3
Factor impacto SCIMAGO: 0.287 - Medicine (miscellaneous) (Q3) - Pharmacology (Q3) - Microbiology (medical) (Q3)
Tipo y forma: Article (Published version)
Área (Departamento): Área Microbiología (Dpto. Microb.Med.Pr.,Sal.Públ.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. Exportado de SIDERAL (2026-01-13-22:07:41)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles > Artículos por área > Microbiología
Record created 2026-01-13, last modified 2026-01-13